From October 5 to 7, 2022, the Congrès de la Société Française de Médecine Prédictive et Personnalisée (SFMPP) brought together experts, researchers and innovative companies around the latest advances in genomics and oncogenomics. Genexpath had the opportunity to present its work as part of the session dedicated to French start-ups and innovation in genomic medicine.
During this presentation, we addressed the theme:
📌 “Optimizing tumor characterization: a new diagnostic approach for sarcomas and lymphomas.”
Sarcomas and lymphomas are particularly complex cancers to diagnose. Accurately classifying them is essential for providing patients with appropriate treatment. Genexpath is developing next-generation diagnostic tests that enable more detailed analysis of these tumors, thereby providing better care.
Watch the replay of our intervention
We invite you to relive our presentation and discover how innovation in oncogenomics contributes to more precise and personalized medicine.
To know more about Genexpath and our advances in genomic medicine, visit our site: 🌐 www.genexpath.com